Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

NCT03070392 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT03070392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03070392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Lead sponsor
Immunocore Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 16, 2017
Completion date
September 17, 2025
Enrollment
378 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma